Mitotic disruption and reduced clonogenicity of pancreatic cancer cells in vitro and in vivo by tumor treating fields

被引:82
作者
Giladi, Moshe [1 ]
Schneiderman, Rosa S. [1 ]
Porat, Yaara [1 ]
Munster, Mijal [1 ]
Itzhaki, Aviran [1 ]
Mordechovich, Daniel [1 ]
Cahal, Shay [1 ]
Kirson, Eilon D. [1 ]
Weinberg, Uri
Palti, Yoram [1 ]
机构
[1] Novocure Ltd, IL-31905 Haifa, Israel
关键词
Anti-mitotic; Cell volume; Clonogenic assay; TTFields; ELECTRIC-FIELDS; DEATH; NOVOTTF-100A; COMBINATION; INHIBITION; APOPTOSIS; PATHWAYS; ONCOSIS; HAMSTER; VOLUME;
D O I
10.1016/j.pan.2013.11.009
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objectives: Tumor Treating Fields (TTFields) are a non-invasive cancer treatment modality approved for the treatment of patients with recurrent glioblastoma. The present study determined the efficacy and mechanism of action of TTFields in preclinical models of pancreatic cancer. Methods: The effect of TTFields in vitro was assessed using cell counts, clonogenic assays, cell cycle analysis and analysis of mitotic figures. The effect in vivo effect was studied in the PC1-0 hamster pancreatic cancer model. Results: Application of TTFields in vitro showed a significant decrease in cell count, an increase in cell volume and reduced clonogenicity. Further analysis demonstrated significant increase in the number of abnormal mitotic figures, as well as a decrease in G2-M cell population. In hamsters with orthotopic pancreatic tumors, TTFields significantly reduced tumor volume accompanied by an increase in the frequency of abnormal mitotic events. TTFields efficacy was enhanced both in vitro and in vivo when combined with chemotherapy. Conclusions: These results provide the first evidence that TTFields serve as an effective antimitotic treatment in preclinical pancreatic cancer models and have a long term negative effect on cancer cell survival. These results make TTFields an attractive candidate for testing in the treatment of patients with pancreatic cancer. Copyright (C) 2013, IAP and EPC. Published by Elsevier India, a division of Reed Elsevier India Pvt. Ltd. All rights reserved.
引用
收藏
页码:54 / 63
页数:10
相关论文
共 29 条
[1]   Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238 [J].
Benali, N ;
Cordelier, P ;
Calise, D ;
Pagès, P ;
Rochaix, P ;
Nagy, A ;
Estève, JP ;
Pour, PM ;
Schally, AV ;
Vaysse, N ;
Susini, C ;
Buscail, L .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (16) :9180-9185
[2]   Pancreatic cancer cell radiation survival and prenyltransferase inhibition: The role of K-ras [J].
Brunner, TB ;
Cengel, KA ;
Hahn, SM ;
Wu, HM ;
Fraker, DL ;
McKenna, WG ;
Bernhard, EJ .
CANCER RESEARCH, 2005, 65 (18) :8433-8441
[3]   INDUCTION OF MULTIFOCAL PANCREATIC-CANCER AFTER INOCULATION OF HAMSTER PANCREATIC-CANCER CELL-LINE (PC-1) INTO A DEFINED AREA OF HOMOLOGOUS PANCREATIC TISSUE [J].
EGAMI, H ;
TAKIYAMA, Y ;
POUR, PM .
CANCER LETTERS, 1990, 50 (01) :53-56
[4]   NovoTTF-100A: a new treatment modality for recurrent glioblastoma [J].
Fonkem, Ekokobe ;
Wong, Eric T. .
EXPERT REVIEW OF NEUROTHERAPEUTICS, 2012, 12 (08) :895-899
[5]   Immunogenic and tolerogenic cell death [J].
Green, Douglas R. ;
Ferguson, Thomas ;
Zitvogel, Laurence ;
Kroemer, Guido .
NATURE REVIEWS IMMUNOLOGY, 2009, 9 (05) :353-363
[6]   LIMITED IN VITRO LIFETIME OF HUMAN DIPLOID CELL STRAINS [J].
HAYFLICK, L .
EXPERIMENTAL CELL RESEARCH, 1965, 37 (03) :614-&
[7]  
Howlader N., 2013, SEER CANC STAT REV
[8]  
HRUBAN RH, 1993, AM J PATHOL, V143, P545
[9]   Discontinuous fragmentation of nuclear DNA during apoptosis revealed by discrete "sub-G1" peaks on DNA content histograms [J].
Kajstura, Malgorzata ;
Halicka, H. Dorota ;
Pryjma, Juliusz ;
Darzynkiewicz, Zbigniew .
CYTOMETRY PART A, 2007, 71A (03) :125-131
[10]   Disruption of cancer cell replication by alternating electric fields [J].
Kirson, ED ;
Gurvich, Z ;
Schneiderman, R ;
Dekel, E ;
Itzhaki, A ;
Wasserman, Y ;
Schatzberger, R ;
Palti, Y .
CANCER RESEARCH, 2004, 64 (09) :3288-3295